Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Mar 2023
Historique:
received: 27 02 2023
revised: 20 03 2023
accepted: 22 03 2023
medline: 14 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: epublish

Résumé

The L-type amino acid transporter (LAT) family contains four members, LAT1~4, which are important amino acid transporters. They mainly transport specific amino acids through cell membranes, provide nutrients to cells, and are involved in a variety of metabolic pathways. They regulate the mTOR signaling pathway which has been found to be strongly linked to cancer in recent years. However, in the field of prostate cancer (PCa), the LAT family is still in the nascent stage of research, and the importance of LATs in the diagnosis and treatment of prostate cancer is still unknown. Therefore, this article aims to report the role of LATs in prostate cancer and their clinical significance and application. LATs promote the progression of prostate cancer by increasing amino acid uptake, activating the mammalian target of rapamycin (mTOR) pathway and downstream signals, mediating castration-resistance, promoting tumor angiogenesis, and enhancing chemotherapy resistance. The importance of LATs as diagnostic and therapeutic targets for prostate cancer was emphasized and the latest research results were introduced. In addition, we introduced selective LAT1 inhibitors, including JPH203 and OKY034, which showed excellent inhibitory effects on the proliferation of various tumor cells. This is the future direction of amino acid transporter targeting therapy drugs.

Identifiants

pubmed: 37047148
pii: ijms24076178
doi: 10.3390/ijms24076178
pmc: PMC10094571
pii:
doi:

Substances chimiques

TOR Serine-Threonine Kinases EC 2.7.11.1
Amino Acids 0
Amino Acid Transport Systems 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Grant-in-Aid for Scientific Research (C)
ID : 20K09555
Organisme : Grant-in-Aid for Scientific Research (B)
ID : 20H03813
Organisme : Japan China Sasakawa Medical Fellowship
ID : N/A

Références

J Neurooncol. 2010 Sep;99(2):217-25
pubmed: 20091333
Int J Biochem Cell Biol. 2015 Oct;67:25-33
pubmed: 26256001
Yakugaku Zasshi. 2021;141(4):501-510
pubmed: 33790117
J Natl Cancer Inst. 2013 Oct 2;105(19):1463-73
pubmed: 24052624
Cancer Sci. 2010 Jan;101(1):173-9
pubmed: 19900191
J Urol. 2016 May;195(5):1588-1597
pubmed: 26682754
J Biol Chem. 1999 Jan 29;274(5):3009-16
pubmed: 9915839
Cell Metab. 2017 Aug 1;26(2):301-309
pubmed: 28768171
EJNMMI Res. 2020 Nov 25;10(1):143
pubmed: 33237350
Prostate. 2017 Feb;77(2):222-233
pubmed: 27696482
Cancers (Basel). 2020 Jul 08;12(7):
pubmed: 32650419
PLoS One. 2016 May 25;11(5):e0156044
pubmed: 27224648
J Biol Chem. 2003 Oct 31;278(44):43838-45
pubmed: 12930836
J Biol Chem. 1999 Jul 9;274(28):19745-51
pubmed: 10391916
Anal Chim Acta. 2015 Apr 22;870:75-82
pubmed: 25819789
Andrology. 2020 Nov;8(6):1844-1858
pubmed: 32741077
In Vivo. 2021 Jul-Aug;35(4):2425-2432
pubmed: 34182526
Cancer Res. 2021 Jul 1;81(13):3664-3678
pubmed: 33985973
Science. 1955 Sep 16;122(3168):501-14
pubmed: 13255879
Pflugers Arch. 2004 Feb;447(5):532-42
pubmed: 14770310
Cancer Res. 2011 Dec 15;71(24):7525-36
pubmed: 22007000
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
J Pharmacol Sci. 2008 Dec;108(4):505-16
pubmed: 19075510
Nat Immunol. 2013 May;14(5):500-8
pubmed: 23525088
Cancers (Basel). 2019 Sep 11;11(9):
pubmed: 31514479
Nature. 2011 Oct 05;478(7368):197-203
pubmed: 21976023
Sci Signal. 2015 Apr 14;8(372):ra34
pubmed: 25872869
Am J Pathol. 2007 Mar;170(3):888-98
pubmed: 17322374
Pharm Res. 2020 May 6;37(5):88
pubmed: 32377929
Int J Cancer. 2006 Aug 1;119(3):484-92
pubmed: 16496379
Eur Urol. 2021 Jun;79(6):717-721
pubmed: 33840559
Int J Pharm. 2013 Feb 25;443(1-2):245-53
pubmed: 23270998
Cancers (Basel). 2022 Jan 04;14(1):
pubmed: 35008399
Eur J Nucl Med Mol Imaging. 2017 May;44(5):812-821
pubmed: 27900521
Sci Rep. 2021 Jun 1;11(1):11478
pubmed: 34075107
J Biol Chem. 1999 Dec 3;274(49):34948-54
pubmed: 10574970
BMC Cancer. 2013 Oct 16;13:482
pubmed: 24131658
Cancer Sci. 2012 Feb;103(2):382-9
pubmed: 22077314
Food Chem Toxicol. 2013 Sep;59:137-44
pubmed: 23747718
Sci Rep. 2020 Jan 28;10(1):1292
pubmed: 31992742
J Nucl Med. 2007 Dec;48(12):2063-71
pubmed: 18056335
ACS Chem Biol. 2014 Jun 20;9(6):1369-76
pubmed: 24762008
Invest New Drugs. 2020 Oct;38(5):1495-1506
pubmed: 32198649
Pathol Int. 2009 Jan;59(1):7-18
pubmed: 19121087
Nucl Med Biol. 2011 Jan;38(1):53-62
pubmed: 21220129
J Am Soc Nephrol. 2009 Jul;20(7):1586-96
pubmed: 19443642
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1195-1206
pubmed: 32212853
J Biol Chem. 1998 Sep 11;273(37):23629-32
pubmed: 9726963
Pathol Res Pract. 2008;204(8):553-61
pubmed: 18440724
J Biol Chem. 1999 Jul 9;274(28):19738-44
pubmed: 10391915
Mol Cell Biol. 2017 May 16;37(11):
pubmed: 28320871
J Biol Chem. 2005 Mar 25;280(12):12002-11
pubmed: 15659399
Amino Acids. 2016 Apr;48(4):1045-1058
pubmed: 26724922
Cancer Sci. 2021 Sep;112(9):3871-3883
pubmed: 34050700
Cancers (Basel). 2020 Nov 15;12(11):
pubmed: 33203154
Nature. 1998 Sep 17;395(6699):288-91
pubmed: 9751058
Transl Oncol. 2021 Jan;14(1):100915
pubmed: 33096335
J Pharmacol Sci. 2017 Feb;133(2):96-102
pubmed: 28242177
Am J Cancer Res. 2015 Mar 15;5(4):1281-94
pubmed: 26101697
BMC Clin Pathol. 2012 Feb 28;12:4
pubmed: 22373026
Hum Pathol. 2019 Feb;84:142-149
pubmed: 30300664
Histol Histopathol. 2014 Feb;29(2):217-27
pubmed: 23824658
Biochem J. 2011 Oct 15;439(2):249-55
pubmed: 21726201
Cancer Sci. 2009 Apr;100(4):753-8
pubmed: 19141127
Semin Cancer Biol. 2005 Aug;15(4):254-66
pubmed: 15916903
Cell Commun Signal. 2019 Jul 25;17(1):83
pubmed: 31345230
Leukemia. 2015 Jun;29(6):1253-66
pubmed: 25482130
Cell Rep. 2017 Dec 26;21(13):3819-3832
pubmed: 29281830
Anticancer Res. 2010 Oct;30(10):4223-7
pubmed: 21036745
Cell Mol Life Sci. 2021 Jan;78(1):195-206
pubmed: 32088728
Genomics. 1998 Jul 15;51(2):282-7
pubmed: 9722952
BMC Cancer. 2013 Oct 30;13:509
pubmed: 24168110
Science. 2016 Jan 1;351(6268):43-8
pubmed: 26449471
Arch Pharm Res. 2007 Apr;30(4):444-52
pubmed: 17489360
Annu Rev Physiol. 2019 Feb 10;81:139-164
pubmed: 30485760
J Physiol. 2015 Mar 1;593(5):1273-89
pubmed: 25480797

Auteurs

Xue Zhao (X)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Shinichi Sakamoto (S)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Jiaxing Wei (J)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Sangjon Pae (S)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Shinpei Saito (S)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Tomokazu Sazuka (T)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Yusuke Imamura (Y)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Naohiko Anzai (N)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Tomohiko Ichikawa (T)

Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH